Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm   
Email ID
Password
Forgotten your password?
Sign me in automatically next time
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Europe
|
US/Canada
|
Japan
|
Asia (excluding Japan)
|
Latin America
|
Rest of World
|
International
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK Promote your vacancy here
Pfizer to bolster rare disease portfolio with FoldRx acquisition
02 September 2010
Pfizer has reiterated its commitment to developing an orphan and rare diseases franchise by acquiring the private US company FoldRx Pharmaceuticals. The two companies did not disclose the financial terms of the acquisition, though Pfizer will make an upfront payment and further payments depending on the achievement of certain milestones. Earlier this year, the pharma giant created a rare disease research unit to discover novel medicines for diseases affecting fewer than 200,000 patients ...
 
Spanish spending on drugs falls as new generic prices bite
01 September 2010
Obligatory price reductions on generic medicines, introduced in Spain to cut the public deficit, are starting to take their toll. National health service spending on pharmaceuticals fell to €977 in July 2010, down by 6.8% compared to the same month in 2009, which the health ministry says is because ...
TiGenix outlines new market-focused strategy
02 September 2010
TiGenix, the Belgium based biotech that spunout its drug discovery activities last week, is focused on becoming a development and marketing company, its CEO Gil Beyen told Scrip. The company spun out its drug discovery activities into new company Arcarios, which was formed with the help of the ...
 
GSK/Valeant's Potiga gets unanimous support from US FDA advisory panel
12 August 2010
The US FDA's peripheral and central nervous system drugs advisory committee on 11 August smoothed the way for approval of the anti-epileptic Potiga (ezogabine, previously known as retigabine), which is being developed under an agreement between GlaxoSmithKline and Valeant (which is in the process ...
US activists petition NIH to break patent on Genzyme's Fabrazyme
05 August 2010
Three US Fabry's disease patients are trying to force the licensing of patents for Genzyme's Fabrazyme (agalsidase beta) to other manufacturers to help alleviate shortages of the drug caused by the company's manufacturing problems. They have petitioned the secretary of the Department of Health and ...
 
Deal with Ono the first for Concordia's novel Ras inhibitor
02 September 2010
Ono Pharmaceutical has acquired exclusive development and commercialisation rights in Japan to Concordia Pharmaceuticals' direct Ras inhibitor salirasib, which it will develop initially for pancreatic cancer. The Japanese firm will pay undisclosed upfront and milestone payments to privately held ...
Xeloda filed in Japan for additional gastric cancer use
02 September 2010
Roche's Japanese subsidiary, Chugai , has made an approval filing for Xeloda (capecitabine) for the treatment of advanced or refractory gastric cancer in patients who are not candidates for curative surgery. The submission follows a formal request from the ministry of health, labour and welfare ...
 
India throws rule book at 'superbug' scientists
02 September 2010
Indian physicians who were involved in the controversial "superbug" NDM-1 study that was published in Lancet Infectious Diseases last month have been asked to confirm whether they followed various national guidelines and procedures required for the transfer of biomedical material outside the ...
Indian managers at multinationals taking on more regional roles
31 August 2010
A number of Indian professional managers who head large multinationals in India are now taking on broader regional responsibilities at these companies as their employers look to develop operations in emerging markets. Dr Shailesh Ayyangar , managing director of Aventis Pharma India and head of ...
 
International formulations business drives Lupin to 21% growth
29 July 2010
Lupin has reported a 21% increase in net sales to Rs13.12 billion ($280.6 million) for the first quarter ended 30 June, led by strong growth in the formulations business in the US and Europe. Net profit rose by 40% to Rs1.96 billion. US and Europe formulation sales increased by 40% to Rs4.96 ...
Masters announces £2.7 million investment and Burns appointment
25 June 2010
Masters Pharmaceuticals, a UK-based healthcare solutions provider specialising in named patient/expanded access programmes for discontinued products, orphan drugs and medicines in clinical development, has secured a £2.65 million investment from venture capitalists Albion Ventures. The new funds ...
 
Ranbaxy opens second plant in South Africa
01 September 2010
Ranbaxy Laboratories has opened its second manufacturing facility in South Africa at Roodepoort, Johannesburg, at an investment of $30 million. It will manufacture a range of products including analgesics, cold, cough and flu preparations, antihistamines, antihypertensives and CNS medicines, ...
Indian govt paper to reignite debate on compulsory licensing
24 August 2010
India's department of industrial policy and promotion (DIPP) has put out a "discussion paper" on the controversial subject of compulsory licences, aimed at developing a "predictable environment" for the use of such measures in the area of medicines. The DIPP paper, which seeks the views and ...
 

2010 Scrip 100 - Pharma muscles into emerging markets with M&A
23 August 2010

This year has seen many firms facing patent expiries on core revenue generators. The current ...

2010 Scrip 100 - Mixed fortunes on the R&D front
23 August 2010

Continued problems with anti-obesity drugs, more measures designed to improve R&D efficiency, and ...

2010 Scrip 100 - Changes pharma can believe in?
23 August 2010

Ian Schofield picks some of the most significant developments in the health policy and regulation ...

Private investment round-up: July 2010 - highest monthly investments secured so far this year
18 August 2010
A Scrip analysis has identified 21 companies that raised private investment in July, one up on the ...

Calling German and Spanish Physicists: the EMA Needs You
13 July 2010
Maureen Kenny
German or Spanish physicists hoping for a career change involving a move to London at the end of ...

GW high on pipeline of cannabis extracts
23 August 2010
Katie McQue
GW Pharma has enjoyed recent success with its cannabinoid extract product Sativex (nabiximols), ...

© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm